The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Lipid‐lowering drugs and mitochondrial function: effects of HMG‐CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio
Open accessAbstract
1 Statins inhibit synthesis of mevalonate, a precursor of ubiquinone that is a central compound of the mitochondrial respiratory chain. The main adverse effect of statins is a toxic myopathy possibly related to mitochondrial dysfunction. 2 This study was designed to evaluate the effect of lipid‐lowering drugs on ubiquinone (coenzyme Q10) serum level and on mitochondrial function assessed by blood lactate/pyruvate ratio. 3 Eighty hypercholesterolaemic patients (40 treated by statins, 20 treated by fibrates, and 20 untreated patients, all 80 having total cholesterol levels >6.0 mmol l−1) and 20 healthy controls were included. Ubiquinone serum level and blood lactate/pyruvate ratio used as a test for mitochondrial dysfunction were evaluated in all subjects. 4 Lactate/pyruvate ratios were significantly higher in patients treated by statins than in untreated hypercholesterolaemic patients or in healthy controls (P<0.05 and P<0.001). The difference was not significant between fibrate‐treated patients and untreated patients. 5 Ubiquinone serum levels were lower in statin‐treated patients (0.75 mg l−1±0.04) than in untreated hypercholesterolaemic patients (0.95 mg l−1±0.09; P<0.05). 6 We conclude that statin therapy can be associated with high blood lactate/pyruvate ratio suggestive of mitochondrial dysfunction. It is uncertain to what extent low serum levels of ubiquinone could explain the mitochondrial dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Mitochondrial dysfunction in muscle cells can lead to altered biochemical parameters such as a higher lactate to pyruvate ratio (L/P ratio), but also to development of myopathic symptoms.(20)”
From Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis (2025) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,807
HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
Oates, J. A., Wood, A. J. J., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190105 · Cited by 760
Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy
Pierce, L. R. (1990) · JAMA · doi:10.1001/jama.1990.03450010075034 · Cited by 425
Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy.
Ogasahara, S., Engel, A. G., Frens, D. B., & Mack, D. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.7.2379 · Cited by 365
Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., & Littarru, G. P. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03948.x · Cited by 324
Comparison of current methods for high-density lipoprotein cholesterol quantitation.
Warnick, G. R., Cheung, M. C., & Albers, J. J. (1979) · Clinical Chemistry · doi:10.1093/clinchem/25.4.596 · Cited by 224
Smith, P. F., Eydelloth, R. S., Grossman, S. J., Stubbs, R. J., Schwartz, M. S., Germershausen, J. I., Vyas, K. P., Kari, P. H., & MacDonald, J. S. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24759-0 · Cited by 146
Masters, B. A., Palmoski, M. J., Flint, O. P., Gregg, R. E., Wang‐Iverson, D. B., & Durham, S. K. (1995) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1995.1058 · Cited by 132
Coenzyme Q 10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease
Matthews, P. M., Ford, B., Dandurand, R. J., Eidelman, D. H., O'Connor, D., Sherwin, A. L., Karpati, G., Andermann, F., & Arnold, D. L. (1993) · Neurology · doi:10.1212/wnl.43.5.884 · Cited by 125
Research works printed but not linked: 3
- Chariot P, Ratiney R, Ammi Said M, He ´rigault R, Adnot S, d'Instruction des Arme ´es du Val de Gra ˆce, Paris, for cholesterol measurements, and D. Gouiffes, for excellent technical Gherardi R. Optimal handling of blood samples for routine measurement of lactate and pyruvate. Arch Pathol L ab assistance. Med 1994; 118: 695-697.
- Lactate, pyruvate, and ketone bodies. In T echniques in 2 Stalenhoef AFH, Mol MJT, Stuyt PMJ. Efficacy and diagnostic human biochemical genetics: a laboratory manual, tolerability of simvastatin. Am J Med 1989; 87 (4A): ed. Homme P, Wiley-Liss, New-York. 1991: 285-308. 39S-43S.
- Deslypere JP, Vermeulen A. Rhabdomyolysis and simvasta- J Chromatogr 1985; 342: 35-46. tin. Ann Intern Med 1991; 114: 342.
Cited by
Sorted by citations
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,930
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 799
The toxicology of perfluorooctanoate
Kennedy, G. L., Butenhoff, J. L., Olsen, G. W., O'Connor, J. C., Seacat, A. M., Perkins, R. G., Biegel, L. B., Murphy, S. R., & Farrar, D. G. (2004) · Critical Reviews in Toxicology · doi:10.1080/10408440490464705 · Cited by 742
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 583
Subchronic Toxicity Studies on Perfluorooctanesulfonate Potassium Salt in Cynomolgus Monkeys
Seacat, A. M. (2002) · Toxicological Sciences · doi:10.1093/toxsci/68.1.249 · Cited by 564
The Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
Warren, J. D., Blumbergs, P. C., & Thompson, P. D. (2002) · Muscle & Nerve · doi:10.1002/mus.10053 · Cited by 433
Resistance Exercise Reverses Aging in Human Skeletal Muscle
Melov, S., Tarnopolsky, M. A., Beckman, K. B., Felkey, K., & Hubbard, A. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000465 · Cited by 360
Effect of Coenzyme Q10 on myopathic symptoms in patients treated with statins
Caso, G., Kelly, P., McNurlan, M. A., & Lawson, W. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.12.063 · Cited by 286
Toxicity of Ammonium Perfluorooctanoate in Male Cynomolgus Monkeys after Oral Dosing for 6 Months
Butenhoff, J. L. (2002) · Toxicological Sciences · doi:10.1093/toxsci/69.1.244 · Cited by 259
Effects of statins on mitochondrial pathways
Mollazadeh, H., Tavana, E., Fanni, G., Bo, S., Banach, M., Pirro, M., von Haehling, S., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12654 · Cited by 270
Low-density lipoprotein-independent effects of statins
Davignon, J., & Laaksonen, R. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199912000-00010 · Cited by 242
Chronic heart failure and micronutrients
Witte, K. K., Clark, A. L., & Cleland, J. G. F. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01227-x · Cited by 237
Human skeletal muscle drug transporters determine local exposure and toxicity of statins
Knauer, M. J., Urquhart, B. L., Meyer zu Schwabedissen, H. E., Schwarz, U. I., Lemke, C. J., Leake, B. F., Kim, R. B., & Tirona, R. G. (2010) · Circulation Research · doi:10.1161/circresaha.109.203596 · Cited by 222
New insights into mechanisms of statin-associated myotoxicity
Sirvent, P., Mercier, J. G., & Lacampagne, A. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.12.010 · Cited by 190
Coenzyme Q10 and statins: Biochemical and clinical implications
Littarru, G. P., & Langsjoen, P. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.002 · Cited by 188
Mitochondrial medicine--molecular pathology of defective oxidative phosphorylation.
Fosslien, E. (2001) · PubMed · Cited by 186
Mancini, G. B. J., Baker, S. K., Bergeron, J., FITCHETT, D. H., Frohlich, J. J., Genest, J. J., Gupta, M., Hegele, R. A., Ng, D. S., & Pope, J. E. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.05.007 · Cited by 187
Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis
Fotino, A. D., Thompson‐Paul, A. M., & Bazzano, L. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.040741 · Cited by 185
Comparative Tolerability of the HMG-CoA Reductase Inhibitors
Farmer, J. A., & Torre‐Amione, G. (2000) · Drug Safety · doi:10.2165/00002018-200023030-00003 · Cited by 181
Statin therapy is associated with lower mortality among patients with severe heart failure
Mozaffarian, D., Nye, R., & Levy, W. C. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.01.039 · Cited by 178
Coenzyme Q10 in cardiovascular disease
Pepe, S., Marasco, S., Haas, S. J., Sheeran, F. L., Krum, H., & Rosenfeldt, F. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.02.005 · Cited by 165
Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy
Chang, J. T., Staffa, J. A., Parks, M. A., & Green, L. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.977 · Cited by 152
The role of mitochondria in statin‐induced myopathy
Apostolopoulou, M., Corsini, A., & Roden, M. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12461 · Cited by 142
Molecular clues into the pathogenesis of statin‐mediated muscle toxicity
Baker, S. K. (2005) · Muscle & Nerve · doi:10.1002/mus.20291 · Cited by 137
Prospective Study of Statin Use and Risk of Parkinson Disease
Gao, X. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1060 · Cited by 127
Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway
Do, R., Kiss, R., Gaudet, D., & Engert, J. C. (2008) · Clinical Genetics · doi:10.1111/j.1399-0004.2008.01099.x · Cited by 118
Mabuchi, H., Higashikata, T., Kawashiri, M., Katsuda, S., Mizuno, M., Nohara, A., Inazu, A., Koizumi, J., & Kobayashi, J. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.111 · Cited by 119
Ubiquinone: cholesterol's reclusive cousin
Hargreaves, I. P. (2003) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/000456303321610493 · Cited by 118
Kwak, H.-B., Thalacker-Mercer, A., Anderson, E. J., Lin, C.-T., Kane, D. A., Lee, N.-S., Cortright, R. N., Bamman, M. M., & Neufer, P. D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.449 · Cited by 114
Langsjoen, P. H., & Langsjoen, A. M. (2003) · BioFactors · doi:10.1002/biof.5520180212 · Cited by 112
Mohn, E. S., Kern, H., Saltzman, E. J., Mitmesser, S. H., & McKay, D. L. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10010036 · Cited by 121
Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors
Jamal, S. M., Eisenberg, M. J., & Christopoulos, S. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.12.037 · Cited by 111
Statin myotoxicity: a review of genetic susceptibility factors
Needham, M., & Mastaglia, F. L. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2013.09.011 · Cited by 108
Effects of Troglitazone on HepG2 Viability and Mitochondrial Function
Tirmenstein, M. A. (2002) · Toxicological Sciences · doi:10.1093/toxsci/69.1.131 · Cited by 110
The Roles of Coenzyme Q in Disease: Direct and Indirect Involvement in Cellular Functions
Pallotti, F., Bergamini, C., Lamperti, C., & Fato, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010128 · Cited by 109
Dai, Y.-L., Luk, T.-H., Yiu, K.-H., Wang, M., Yip, P. M. C., Lee, S. W. L., Li, S.-W., Tam, S., Fong, B., Lau, C.-P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.013 · Cited by 104
Coenzyme Q10 Supplementation and Heart Failure
Singh, U. S., Devaraj, S., & Jialal, I. (2007) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00306.x · Cited by 104
Statin‐associated myopathy and its exacerbation with exercise
Meador, B. M., & Huey, K. A. (2010) · Muscle & Nerve · doi:10.1002/mus.21817 · Cited by 99
Strey, C. H., Young, J. M., Molyneux, S. L., George, P. M., Florkowski, C. M., Scott, R. S., & FRAMPTON, C. M. A. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.10.009 · Cited by 93
Hargreaves, I. P., Duncan, A. J., Heales, S. J. R., & Land, J. M. (2005) · Drug Safety · doi:10.2165/00002018-200528080-00002 · Cited by 91
Statin myopathies: pathophysiologic and clinical perspectives.
Baker, S. K., & Tarnopolsky, M. A. (2001) · PubMed · Cited by 90
Effect of Coenzyme Q10 supplementation on statin-induced myalgias
Bookstaver, D. A., Burkhalter, N. A., & Hatzigeorgiou, C. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.026 · Cited by 89
Mitochondrial Dysfunction as an Initiating Event in Atherogenesis: A Plausible Hypothesis
Puddu, P., Puddu, G. M., Galletti, L., Cravero, E., & Muscari, A. (2005) · Cardiology · doi:10.1159/000083440 · Cited by 86
Coenzyme Q10: is there a clinical role and a case for measurement?
Molyneux, S. L., Young, J. M., Florkowski, C. M., Lever, M., & George, P. M. (2008) · PubMed Central · Cited by 87
Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma
Berthold, H. K., Naini, A., Mauro, S. D., Hallikainen, M., Gylling, H. K., Krone, W., & Gouni‐Berthold, I. (2006) · Drug Safety · doi:10.2165/00002018-200629080-00007 · Cited by 87
Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era
Vittecoq, D., Escaut, L., Chironi, G. N., Teicher, E., Monsuez, J. J., Andréjak, M., & Simon, A. C. (2003) · AIDS · doi:10.1097/00002030-200304001-00010 · Cited by 84
Muntean, D. M., Thompson, P. D., Catapano, A. L., Stasiolek, M., Fabis, J., Muntner, P., Serban, M.-C., & Banach, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.001 · Cited by 82
Clinical Implications of Pharmacogenetic Variation on the Effects of Statins
Maggo, S. D. S., Kennedy, M. A., & Clark, D. W. J. (2010) · Drug Safety · doi:10.2165/11584380-000000000-00000 · Cited by 83
HMG-CoA reductase inhibitors and coenzyme Q10
Nawarskas, J. J. (2005) · Cardiology in Review · doi:10.1097/01.crd.0000154790.42283.a1 · Cited by 80
Wang, Y., Lilienfeldt, N., & Hekimi, S. (2024) · Physiological Reviews · doi:10.1152/physrev.00040.2023 · Cited by 88
From Mitochondria to Atherosclerosis: The Inflammation Path
Suarez-Rivero, J. M., Pastor‐Maldonado, C. J., Povea-Cabello, S., Álvarez-Córdoba, M., Villalón-García, I., Talaverón-Rey, M., Suárez-Carrillo, A., Munuera-Cabeza, M., & Sánchez-Alcázar, J. A. (2021) · Biomedicines · doi:10.3390/biomedicines9030258 · Cited by 78
Statins induce calcium-dependent mitochondrial permeability transition
Velho, J. A., Okanobo, H., Degasperi, G. R., Matsumoto, M. Y., Alberici, L. C., Cosso, R. G., Oliveira, H. C. F., & Vercesi, A. E. (2005) · Toxicology · doi:10.1016/j.tox.2005.11.007 · Cited by 77
Presymptomatic Neuromuscular Disorders Disclosed Following Statin Treatment
Tsivgoulis, G. K., Spengos, K. M., Karandreas, N., Πάνας, Μ., Kladi, A., & Manta, P. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.14.1519 · Cited by 77
Roles of Exercise and Pharmacokinetics in Cerivastatin-Induced Skeletal Muscle Toxicity
Seachrist, J. L., Loi, C., Evans, M. G., Criswell, K. A., & Rothwell, C. E. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi305 · Cited by 77
The effect of pravastatin and atorvastatin on coenzyme Q10
Bleske, B. E., Willis, R. A., Anthony, M. J., Casselberry, N., Datwani, M., Uhley, V. E., Secontine, S. G., & Shea, M. J. (2001) · American Heart Journal · doi:10.1067/mhj.2001.116762 · Cited by 77
Yang, Y., Jan, Y., Liu, Y., Yang, C., Su, C., Chang, Y., Lai, T., Chiou, J., Tsai, H., Lu, J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201404-0714oc · Cited by 77
Cerivastatin Improves Insulin Sensitivity and Insulin Secretion in Early-State Obese Type 2 Diabetes
Paniagua, J. A., López‐Miranda, J., Escribano, A., Berral, F. J., Marı́n, C., Bravo, D., Paz-Rojas, E., Gomez, P. J., Barcos, M., Moreno, J. A., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2596 · Cited by 74
Effects of ubiquinone (coenzyme Q10) on myopathy in statin users
Schaars, C. F., & Stalenhoef, A. F. H. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283168ecd · Cited by 74
Inhibition of mitochondrial respiratory chain is involved in triptolide-induced liver injury
Fu, Q., Huang, X., Shu, B., Xue, M., Zhang, P., Wang, T., Liu, L., Jiang, Z., & Zhang, L. (2011) · Fitoterapia · doi:10.1016/j.fitote.2011.08.019 · Cited by 71
Analysis of the Global RNA Expression Profiles of Skeletal Muscle Cells Treated with Statins
Morikawa, S., Murakami, T., Yamazaki, H., Izumi, A., Saitō, Y., Hamakubo, T., & Kodama, T. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.121 · Cited by 70
Association between risk of myopathy and cholesterol-lowering effect: A comparison of all statins
Kobayashi, M., Chisaki, I., Narumi, K., Hidaka, K., Kagawa, T., Itagaki, S., Hirano, T., & Iseki, K. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.02.019 · Cited by 66
Treatment of hyperlipidemia in cardiac transplant recipients
Bilchick, K. C., Henrikson, C. A., Skojec, D. V., Kasper, E. K., & Blumenthal, R. S. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.03.050 · Cited by 66
Drug-Induced Mitochondrial Toxicity
Hargreaves, I. P., Shahrani, M. M. A., Wainwright, L., & Heales, S. (2016) · Drug Safety · doi:10.1007/s40264-016-0417-x · Cited by 63
Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
Schmitz, G., & Drobnik, W. (2003) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2003.088 · Cited by 64
Tiziani, S., Kang, Y., Choi, J. S., Roberts, W., & Paternostro, G. (2011) · Nature Communications · doi:10.1038/ncomms1562 · Cited by 60
Lipid-Lowering Drugs: Are Adverse Effects Predictable and Reversible?
Muscari, A., Puddu, G. M., & Puddu, P. (2002) · Cardiology · doi:10.1159/000063326 · Cited by 59
Potential role of coenzyme Q10 in health and disease conditions
Rodick, T. C., Seibels, D. R., Babu, J. R., Huggins, K. W., Ren, G., & Mathews, S. T. (2018) · Nutrition and Dietary Supplements · doi:10.2147/nds.s112119 · Cited by 58
Passi, S., Stancato, A., Aleo, E., Dmitrieva, A., & Littarru, G. P. (2003) · BioFactors · doi:10.1002/biof.5520180213 · Cited by 57
Conceptual Foundations of the UCSD Statin Study
Golomb, B. A., Criqui, M. H., White, H., & Dimsdale, J. E. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.2.153 · Cited by 58
Polymyosites induites ou associées aux traitements hypolipémiants ?
Fauchais, A. L., Ba, J. I., Maurage, P., Kyndt, X., Bataille, D., HACHULLA, E., Parent, D., Queyrel, V., Lambert, M., Pasturel, U. M., et al. (2003) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2003.10.013 · Cited by 57
Garjani, A., Andalib, S., Biabani, S., Soraya, H., Doustar, Y., Garjani, A., & Maleki‐Dizaji, N. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.061 · Cited by 54
Statins in the treatment of chronic heart failure: Biological and clinical considerations
van der Harst, P., Voors, A. A., van Gilst, W. H., Böhm, M., & VANVELDHUISEN, D. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.04.011 · Cited by 55
Egom, E. E. A., & Hafeez, H. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.10.005 · Cited by 57
Coenzyme Q10: A therapy for hypertension and statin-induced myalgia?
Wyman, M. J., Leonard, M. C., & Morledge, T. J. (2010) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77a.09078 · Cited by 52
Rosuvastatin: Characterization of Induced Myopathy in the Rat
Westwood, F. R., Scott, R. C., Marsden, A. M., Bigley, A. L., & Randall, K. (2008) · Toxicologic Pathology · doi:10.1177/0192623307311412 · Cited by 51
de Lorgeril, M., Salen, P., Bontemps, L., Bélichard, P., GEYSSANT, A., & Itti, R. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199903000-00018 · Cited by 51
Implications of statin adverse effects in the elderly
Golomb, B. A. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.3.389 · Cited by 49
Statins and Modulation of Oxidative Stress
Bełtowski, J. (2005) · Toxicology Mechanisms and Methods · doi:10.1080/15376520590918766 · Cited by 49
Golomb, B. A., Kwon, E. K., Koperski, S., & Evans, M. A. (2009) · Drug Safety · doi:10.2165/00002018-200932080-00004 · Cited by 48
Guardia, P. G. L., Alberici, L. C., Ravagnani, F. G., Catharino, R. R., & Vercesi, A. E. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00103 · Cited by 46
A Neuromuscular Approach to Statin-Related Myotoxicity
Baker, S. K., & Samjoo, I. A. (2008) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100007514 · Cited by 45
Coenzyme Q10 and Statin Myalgia: What is the Evidence?
Mas, E., & Mori, T. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0134-3 · Cited by 43
The effects of statins on exercise and physical activity
Noyes, A. M., & Thompson, P. D. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.003 · Cited by 44
Targeting cellular energy production in neurological disorders
Baker, S. K., & Tarnopolsky, M. A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.10.1655 · Cited by 43
Andalib, S., Mashhadi-Mousapour, M., Bijani, S., & Hosseini, M.-J. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02761-0 · Cited by 43
Coronary Heart Disease in HIV-Infected Individuals
Vittecoq, D., Escaut, L., Merad, M., Teicher, E., Monsuez, J.-J., & Chironi, G. N. (2003) · KARGER eBooks · doi:10.1159/000073181 · Cited by 42
Protective Effects of Coenzyme Q10 on Decreased Oxidative Stress Resistance Induced by Simvastatin
Kettawan, A., Takahashi, T., Kongkachuichai, R., Charoenkiatkul, S., Kishi, T., & Okamoto, T. (2007) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.40.194 · Cited by 41
Considerations for Supplementing with Coenzyme Q 10 During Statin Therapy
Levy, H. B., & Kohlhaas, H. K. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g409 · Cited by 37
Potential metabolic consequences of statins in sepsis*
Brealey, D. A., Singer, M., & Terblanche, M. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e31820eb74f · Cited by 36
The controversy of a wider statin utilization: why?
Mansi, I. A., & Mortensen, E. M. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.779667 · Cited by 37
Goodman, C. A., Derk, P., Zacharewicz, E., Lee, R. S., Snow, R. J., Russell, A. P., & McConell, G. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128398 · Cited by 35
Negvesky, G. J., Kolsky, M. P., Laureno, R., & Yau, T. H. (2000) · Archives of Ophthalmology · doi:10.1001/archopht.118.3.427 · Cited by 35
Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia
Gheith, O. A. A., Sheashaa, H., Abdelsalam, M. A. M., Shoeir, Z., & Sobh, M. A. K. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0033-x · Cited by 35
Cai, Y., Xing, G., Tian, S., Zhang, S., Rao, J., & Shi, R. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0640-1 · Cited by 33
Drug-induced mitochondrial dysfunction in cardiac and skeletal muscle injury
Sardão, V. A., Pereira, S. L., & Oliveira, P. J. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.2.129 · Cited by 34
Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure
Bielecka-Dabrowa, A. M., Fabiś, J., Mikhailidis, D. P., von Haehling, S., Sahebkar, A., Rysz, J., & Banach, M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.003 · Cited by 30
Biomarkers of Metabolism in Amyotrophic Lateral Sclerosis
Kirk, S. E., Tracey, T. J., Steyn, F. J., & Ngo, S. T. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00191 · Cited by 38
Metadata
- Authors
- DE PINIEUX, G., CHARIOT, P., AMMI‐SAÏD, M., LOUARN, F., LEJONC, J. L., ASTIER, A., JACOTOT, B., & GHERARDI, R.
- Affiliations
- Hôpital Albert-Chenevier (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Corresponding author
- CHARIOT, P.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1996-09
- Volume
- 42
- Issue
- 3
- Pages
- 333-337
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- PMC
- PMC2042680
- OpenAlex
- W2095119347
- Cited by
- 262
- References
- 26
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 6 · 2023: 1 · 2022: 2 · 2021: 9 · 2020: 4 · 2019: 8 · 2018: 10 · 2017: 5 · 2016: 10 · 2015: 9 · 2014: 9 · 2013: 6 · 2012: 18
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Clinical Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, mitochondrial dysfunction, coenzyme Q10, lactate/pyruvate ratio, statin-induced myopathy, hypercholesterolemia, fibrates, lipid-lowering drugs, mevalonate
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Mitochondria, Ubiquinone, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Pyruvic Acid, Lactic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
